Drug Overview

Tivozanib hydrochloride is a highly specialized cancer medication designed to target and slow the growth of specific tumors. Often referred to as a “Smart Drug” or “Targeted Therapy,” it is used when traditional treatments have stopped working. Below are the essential details about this medication:

Generic Name: Tivozanib hydrochloride
US Brand Names: FOTIVDA®
Drug Class: Kinase Inhibitor / Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor
Route of Administration: Oral (capsule)
FDA Approval Status: FDA approved on March 10, 2021, for specific types of advanced kidney cancer.

What Is It and How Does It Work? (Mechanism of Action)

Tivozanib hydrochloride is an oral “Targeted Therapy” that fights cancer by cutting off the tumor’s food and oxygen supply. Tumors need a network of blood vessels to grow and spread. They create these blood vessels by releasing chemical signals into the body, a process known as angiogenesis.

At the molecular level, tivozanib works by blocking the specific receptors that receive these signals. It targets three specific proteins on the surface of blood vessel cells: VEGFR-1, VEGFR-2, and VEGFR-3. When the drug binds to the internal parts of these receptors (the tyrosine kinase domains), it acts like a switch that turns the receptor off. This stops a chain reaction of signals inside the cell, such as the MAPK/ERK and PI3K/AKT pathways, which normally tell the cell to divide and survive.

Because tivozanib is highly selective, it specifically stops new blood vessels from forming around the tumor without heavily affecting other healthy cellular processes. By starving the cancer cells of the blood supply they need, the drug helps to halt tumor growth and can cause the tumor to shrink.

FDA-Approved Clinical Indications

Because it is a highly specialized targeted therapy, tivozanib is currently only approved for specific cancerous conditions.

Oncological Uses:
- Treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC), which is a type of kidney cancer. It is specifically approved for patients who have already tried two or more prior systemic therapies that are no longer working.
Non-oncological Uses:
- None. This drug is exclusively used for cancer treatment.

Dosage and Administration Protocols

Tivozanib is taken as a pill at home, which makes it a convenient option for patients. It is given in a 28-day cycle, meaning the patient takes the medication for a set number of days and then rests.

Treatment Detail	Protocol Specification
Standard Dose	1.34 mg capsule taken orally once daily.
Frequency	21 days ON treatment, followed by 7 days OFF treatment (28-day cycle).
Infusion Time	Not applicable; this is an oral capsule, not an IV infusion.
Hepatic (Liver) Impairment	Mild: No adjustment. Moderate: Reduce dose to 0.89 mg once daily (21 days on, 7 days off). Severe: Not recommended.
Renal (Kidney) Impairment	Mild to Moderate: No adjustment. Severe or Dialysis: No established dose; use with extreme caution.
Toxicity Adjustments	If severe side effects occur, the dose may be reduced to 0.89 mg once daily or paused until the side effects improve

Clinical Efficacy and Research Results

Recent clinical studies between 2020 and 2025 have shown that tivozanib is a reliable and effective option for patients with hard-to-treat kidney cancer.

The FDA approval was largely based on the Phase 3 TIVO-3 trial. In this study of 350 patients with advanced kidney cancer, tivozanib was compared to another targeted drug called sorafenib.

Disease Progression: Patients taking tivozanib lived significantly longer without their disease getting worse. The median progression-free survival (PFS) was 5.6 months for tivozanib, compared to 3.9 months for sorafenib.
Response Rates: The objective response rate (the percentage of patients whose tumors shrank significantly) was 18% for tivozanib, compared to just 8% for sorafenib.
Recent Real-World Data (2024-2025): Long-term follow-up data from the TIVO-3 study showed that even in patients who had previously failed modern immunotherapy treatments, tivozanib continued to show strong results, providing a median progression-free survival of 7.3 months. Overall survival rates hovered around 16.4 months.

Safety Profile and Side Effects

Like all cancer treatments, tivozanib can cause side effects. Because it changes how blood vessels behave, many of its side effects are related to the cardiovascular system.

FDA Black Box Warning: There is no FDA Black Box Warning for tivozanib. However, the FDA label includes serious warnings about cardiovascular risks that require close medical attention.

Common Side Effects (>10%)

Fatigue: Feeling unusually tired or weak.
Hypertension (High Blood Pressure): This is very common and affects over 20% of patients severely.
Gastrointestinal Issues: Diarrhea, nausea, and decreased appetite.
Dysphonia: Hoarseness or changes in the voice.
Cough and Mouth Sores: Mild irritation in the throat and mouth (stomatitis).

Serious Adverse Events

Severe Hypertension and Hypertensive Crisis: Blood pressure can rise to dangerous levels.
Bleeding Events: Because the drug affects blood vessels, there is a risk of severe bleeding (hemorrhage).
Blood Clots: Arterial thromboembolic events, such as heart attacks or strokes, can occur.
Proteinuria: High levels of protein in the urine indicate kidney stress.
Heart Failure: The heart may struggle to pump blood effectively.

Management Strategies

Blood Pressure Control: High blood pressure must be treated with standard blood pressure medications. If it remains dangerously high, the tivozanib dose must be lowered or paused.
Symptom Relief: Anti-diarrhea and anti-nausea medications should be used early to manage stomach issues.
Dose Reduction: If a patient experiences a severe reaction, the doctor will likely lower the daily dose from 1.34 mg to 0.89 mg to help the body recover while still fighting the cancer.

Connection to Stem Cell and Regenerative Medicine (If Applicable)

While tivozanib is not a stem cell therapy, it is highly active in the field of advanced Immunotherapy research. Recent major clinical trials, such as the TiNivo-2 trial (published in late 2024 and 2025), have studied how tivozanib interacts with the body’s immune system. Tumors often use VEGF signals to create a “shield” that hides them from the body’s natural immune cells.

By blocking these signals, tivozanib was thought to break down this shield, potentially making immune-boosting drugs (like nivolumab) work better. Interestingly, recent 2025 data revealed that using tivozanib by itself was actually highly effective as a second-line defense for patients whose cancers had already resisted previous immunotherapy, proving its power as a standalone targeted treatment in modern cancer care.

Patient Management and Practical Recommendations

To keep patients safe and ensure the medication works as well as possible, healthcare teams follow strict management guidelines.

Pre-treatment Tests to be Performed

Blood Pressure Check: Blood pressure must be well-controlled before starting the first pill.
Urine Test (Urinalysis): To check for protein in the urine, ensuring the kidneys are healthy enough for treatment.
Blood Tests: To check thyroid function, liver function, and sodium levels.
Pregnancy Test: A negative pregnancy test is required for females of reproductive age, as this drug can cause severe harm to an unborn baby.

Precautions During Treatment

Wound Healing: Tivozanib stops new blood vessels from forming, which means cuts and surgical wounds will not heal properly. The drug must be stopped for at least 24 days before any planned surgery, including major dental work.
Heart and Clot Monitoring: Patients must be monitored for chest pain, sudden weakness, or leg swelling, which could indicate a blood clot.

“Do’s and Don’ts” List

DO take your capsule at the same time every day, with or without food.
DO swallow the capsule whole with a glass of water.
DO check your blood pressure at home regularly and log the numbers for your doctor.
DO use effective birth control during treatment and for at least one month after your last dose.
DON’T open, crush, or chew the capsules.
DON’T take two doses at the same time. If you miss a dose, skip it and take your next dose at the regularly scheduled time.
DON’T breastfeed while taking this medication and for one month after stopping.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Tivozanib hydrochloride is a prescription medication and should only be used under the direct supervision of a qualified healthcare professional or treating oncologist. Always consult with your doctor regarding diagnosis, treatment options, potential drug interactions, and to see if this therapy is appropriate for your specific medical condition.